Charles Schwab Investment Management Inc. Buys 42,539 Shares of Bausch Health Companies Inc. (NYSE:BHC)

Charles Schwab Investment Management Inc. lifted its position in Bausch Health Companies Inc. (NYSE:BHC) by 3.5% during the 3rd quarter, Holdings Channel reports. The firm owned 1,269,478 shares of the company’s stock after acquiring an additional 42,539 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Bausch Health Companies were worth $10,373,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in BHC. Headlands Technologies LLC bought a new stake in shares of Bausch Health Companies in the 2nd quarter worth approximately $35,000. MQS Management LLC bought a new position in Bausch Health Companies in the second quarter worth $71,000. Certuity LLC purchased a new position in Bausch Health Companies during the second quarter valued at $75,000. Bfsg LLC boosted its holdings in shares of Bausch Health Companies by 46.7% during the 2nd quarter. Bfsg LLC now owns 11,450 shares of the company’s stock valued at $80,000 after buying an additional 3,643 shares in the last quarter. Finally, Kendall Capital Management purchased a new stake in shares of Bausch Health Companies in the 2nd quarter worth about $87,000. 78.65% of the stock is owned by hedge funds and other institutional investors.

Bausch Health Companies Stock Performance

Shares of Bausch Health Companies stock opened at $8.46 on Tuesday. The stock has a market cap of $3.06 billion, a P/E ratio of -17.61 and a beta of 0.69. The stock’s fifty day moving average is $8.41 and its 200 day moving average is $7.21. Bausch Health Companies Inc. has a one year low of $3.96 and a one year high of $11.46.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.10. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The business had revenue of $2.51 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter in the previous year, the firm earned $1.03 earnings per share. The company’s revenue for the quarter was up 12.2% on a year-over-year basis. Analysts predict that Bausch Health Companies Inc. will post 3.74 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. Evercore ISI raised Bausch Health Companies to a “hold” rating in a report on Tuesday, October 15th. Finally, Royal Bank of Canada lifted their target price on shares of Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, Bausch Health Companies presently has a consensus rating of “Hold” and a consensus target price of $7.75.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.